Literature DB >> 24029142

Induction of homologous recombination following in utero exposure to DNA-damaging agents.

Bijal Karia1, Jo Ann Martinez, Alexander J R Bishop.   

Abstract

Much of our understanding of homologous recombination, as well as the development of the working models for these processes, has been derived from extensive work in model organisms, such as yeast and fruit flies, and mammalian systems by studying the repair of induced double strand breaks or repair following exposure to genotoxic agents in vitro. We therefore set out to expand this in vitro work to ask whether DNA-damaging agents with varying modes of action could induce somatic change in an in vivo mouse model of homologous recombination. We exposed pregnant dams to DNA-damaging agents, conferring a variety of lesions at a specific time in embryo development. To monitor homologous recombination frequency, we used the well-established retinal pigment epithelium pink-eyed unstable assay. Homologous recombination resulting in the deletion of a duplicated 70 kb fragment in the coding region of the Oca2 gene renders this gene functional and can be visualized as a pigmented eyespot in the retinal pigment epithelium. We observed an increased frequency of pigmented eyespots in resultant litters following exposure to cisplatin, methyl methanesulfonate, ethyl methanesulfonate, 3-aminobenzamide, bleomycin, and etoposide with a contrasting decrease in the frequency of detectable reversion events following camptothecin and hydroxyurea exposure. The somatic genomic rearrangements that result from such a wide variety of differently acting damaging agents implies long-term potential effects from even short-term in utero exposures.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DNA damaging agents; Homologous recombination; In utero exposure; In vivo; Mouse; Pink-eyed unstable

Mesh:

Substances:

Year:  2013        PMID: 24029142      PMCID: PMC4059048          DOI: 10.1016/j.dnarep.2013.08.005

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  75 in total

1.  Detection of somatic DNA recombination in the transgenic mouse brain.

Authors:  M Matsuoka; F Nagawa; K Okazaki; L Kingsbury; K Yoshida; U Müller; D T Larue; J A Winer; H Sakano
Journal:  Science       Date:  1991-10-04       Impact factor: 47.728

2.  Risk of cancer among children exposed in utero to A-bomb radiations, 1950-84.

Authors:  Y Yoshimoto; H Kato; W J Schull
Journal:  Lancet       Date:  1988-09-17       Impact factor: 79.321

3.  Chromosomal aberrations in cord blood are associated with prenatal exposure to carcinogenic polycyclic aromatic hydrocarbons.

Authors:  Kirsti A Bocskay; Deliang Tang; Manuela A Orjuela; Xinhua Liu; Dorothy P Warburton; Frederica P Perera
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

4.  Atm-, p53-, and Gadd45a-deficient mice show an increased frequency of homologous recombination at different stages during development.

Authors:  Alexander J R Bishop; M Christine Hollander; Bela Kosaras; Richard L Sidman; Albert J Fornace; Robert H Schiestl
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

5.  Cytotoxicity and sister chromatid exchanges induced in vitro by six anticancer drugs developed in the People's Republic of China.

Authors:  C C Huang; C S Han; X F Yue; C M Shen; S W Wang; F G Wu; B Xu
Journal:  J Natl Cancer Inst       Date:  1983-10       Impact factor: 13.506

6.  PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites.

Authors:  Jean-François Haince; Darin McDonald; Amélie Rodrigue; Ugo Déry; Jean-Yves Masson; Michael J Hendzel; Guy G Poirier
Journal:  J Biol Chem       Date:  2007-11-19       Impact factor: 5.157

7.  Correlation of sister chromatid exchange formation through homologous recombination with ribonucleotide reductase inhibition.

Authors:  Atsuko Matsuoka; Cecilia Lundin; Fredrik Johansson; Margareta Sahlin; Kiyoshi Fukuhara; Britt-Marie Sjöberg; Dag Jenssen; Agneta Onfelt
Journal:  Mutat Res       Date:  2004-03-22       Impact factor: 2.433

Review 8.  Overview of perinatal and multigeneration carcinogenesis.

Authors:  L Tomatis
Journal:  IARC Sci Publ       Date:  1989

9.  Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics.

Authors:  Kristina Trenz; Sebastian Lugowski; Ute Jahrsdörfer; Silke Jainta; Walther Vogel; Günter Speit
Journal:  Mutat Res       Date:  2003-11       Impact factor: 2.433

10.  The topoisomerase I inhibitors, camptothecin and beta-lapachone, induce apoptosis of human retinal pigment epithelial cells.

Authors:  A Hueber; P Esser; K Heimann; N Kociok; S Winter; M Weller
Journal:  Exp Eye Res       Date:  1998-11       Impact factor: 3.770

View more
  2 in total

1.  Safety assessment of titanium dioxide (E171) as a food additive.

Authors:  Maged Younes; Gabriele Aquilina; Laurence Castle; Karl-Heinz Engel; Paul Fowler; Maria Jose Frutos Fernandez; Peter Fürst; Ursula Gundert-Remy; Rainer Gürtler; Trine Husøy; Melania Manco; Wim Mennes; Peter Moldeus; Sabina Passamonti; Romina Shah; Ine Waalkens-Berendsen; Detlef Wölfle; Emanuela Corsini; Francesco Cubadda; Didima De Groot; Rex FitzGerald; Sara Gunnare; Arno Christian Gutleb; Jan Mast; Alicja Mortensen; Agnes Oomen; Aldert Piersma; Veronika Plichta; Beate Ulbrich; Henk Van Loveren; Diane Benford; Margherita Bignami; Claudia Bolognesi; Riccardo Crebelli; Maria Dusinska; Francesca Marcon; Elsa Nielsen; Josef Schlatter; Christiane Vleminckx; Stefania Barmaz; Maria Carfí; Consuelo Civitella; Alessandra Giarola; Ana Maria Rincon; Rositsa Serafimova; Camilla Smeraldi; Jose Tarazona; Alexandra Tard; Matthew Wright
Journal:  EFSA J       Date:  2021-05-06

2.  ATR suppresses endogenous DNA damage and allows completion of homologous recombination repair.

Authors:  Adam D Brown; Brian W Sager; Aparna Gorthi; Sonal S Tonapi; Eric J Brown; Alexander J R Bishop
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.